11月19日港股创新药ETF（513120）份额增加2150.00万份

Core Points - The Hong Kong Innovative Drug ETF (513120) experienced a decline of 0.52% on November 19, with a trading volume of 5.353 billion yuan [1] - The ETF's shares increased by 21.5 million, bringing the total shares to 18.636 billion, with a notable increase of 1.975 billion shares over the past 20 trading days [1] - The latest net asset value of the ETF is calculated at 24.997 billion yuan [1] - The performance benchmark for the ETF is the return rate of the CSI Hong Kong Innovative Drug Index (in RMB) [1] - Managed by Guangfa Fund Management Co., Ltd., the fund manager is Liu Jie, and since its inception on July 1, 2022, it has achieved a return of 34.12%, while the return over the past month is -2.04% [1]